MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel discussion on Cardiology at 7:45am ET and a company presentation at 9:15am ET. The conference will be held at the Roosevelt Hotel in New York City.
A live audio webcast of the presentation will be available at the following URL:
About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.Investor Contact Information: Stephen SchultzInvestor Relations and Corporate CommunicationsAmarin CorporationIn U.S.: +1 (860) 572-4979 x292 email@example.com Le